Review article: the pharmacology of rabeprazole

Williams, Margaret; Pounder, RE

doi:10.1046/j.1365-2036.1999.00019.x

Cited by 74 publications

(74 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[97,[101][102][103][104][105][106][107] Thus, the MIC range against H. pylori for rabeprazole is considerably lower than that previously reported for omeprazole or lansoprazole. [97,[101][102][103][104][105][106][107][108] Furthermore, in vitro, rabeprazole inhibits H. pylori motility [105,106] and urease activity. [109,110] However, but for some exceptions, rabeprazole monotherapy has not been able to eradicate H. pylori infection.…”

Section: Rabeprazolementioning

confidence: 98%

“…[62,[95][96][97][98][99] However, this PPI has shown itself to have a greater anti-secretory potency and is associated with a faster onset of action than other PPIs (such as omeprazole) at equivalent doses. [62,[95][96][97][98][99] This PPI has been shown to have high anti-secretory efficacy in H. pylori-infected subjects. [100] On the other hand, a number of studies have shown that rabeprazole shows greater 88 Gisbert Fig.…”

Section: Rabeprazolementioning

confidence: 99%

“…[63,[95][96][97][98] Yet rabeprazole has a higher anti-secretory potency and is associated with a faster onset of action than other PPIs such as omeprazole at equivalent doses. [62,[95][96][97][98][99] However, this PPI has shown itself to have a greater anti-secretory potency and is associated with a faster onset of action than other PPIs (such as omeprazole) at equivalent doses. [62,[95][96][97][98][99] This PPI has been shown to have high anti-secretory efficacy in H. pylori-infected subjects.…”

Section: Rabeprazolementioning

confidence: 99%

“…The results achieved with this new PPI in both gastro-oesophageal reflux disease and peptic ulcer disease have been at least similar to those previously reported for other 'older' PPIs such as omeprazole or lansoprazole. [63,[95][96][97][98] Yet rabeprazole has a higher anti-secretory potency and is associated with a faster onset of action than other PPIs such as omeprazole at equivalent doses. [62,[95][96][97][98][99] However, this PPI has shown itself to have a greater anti-secretory potency and is associated with a faster onset of action than other PPIs (such as omeprazole) at equivalent doses.…”

Section: Rabeprazolementioning

confidence: 99%

See 3 more Smart Citations

Potent Gastric Acid Inhibition in Helicobacter pylori Eradication

Gisbert

2005

Drugs

View full text Add to dashboard Cite

At present, antisecretory drugs -foremost among them the proton pump inhibitors (PPIs) -represent a keystone in Helicobacter pylori eradication therapy. The present article shall first compare the role of PPIs as compared with histamine H 2 receptor antagonists, both of them in the role of antibiotic-associated antisecretory therapy, and shall then address the contribution of each of the various PPIs that have been developed until the present time to the H. pylori eradication therapies. In summary, it may be concluded that PPIs are more effective overall than H 2 receptor antagonists when the two groups of antisecretory drugs are given at the usual standard doses together with antibiotics with the intention of eradicating H. pylori infection. However, all PPIs (omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole) are equivalent when given together with two antibiotics to cure the infection.

show abstract

Section: Rabeprazolementioning

confidence: 98%

Section: Rabeprazolementioning

confidence: 99%

Section: Rabeprazolementioning

confidence: 99%

Section: Rabeprazolementioning

confidence: 99%

See 2 more Smart Citations

Potent Gastric Acid Inhibition in Helicobacter pylori Eradication

Gisbert

2005

Drugs

View full text Add to dashboard Cite

show abstract

“…PPIs are completely eliminated after hepatic biotransformation. Elimination is predominantly via bile [37][38][39] .…”

Section: Discussionmentioning

confidence: 99%

Effect of Proton Pump Inhibitors on Hepatic Regeneration

et al. 2006

View full text Add to dashboard Cite

Introduction: The liver is critical in multiple processes, including the clearance of endogenous compounds, the synthesis of macromolecules, and organ-specific biotransformation processes. Therefore, the liver’s regenerating capacity is of vital importance. Multiple pathways are activated in the complex process that leads to hepatic regeneration. In the present study, we aimed to evaluate the effect of proton pump inhibitors omeprozole, lansoprazole, and pantoprazole on hepatic regeneration following partial hepatectomy. Materials and Methods: Four groups were formed with 32 rats in each. Partial liver resections were performed for all animals. Omeprazole (71.4 µg/day), lansoprazole (107 µg/day), pantoprazole (143 µg/day) and placebo (0.5 cm³) were administered to the groups respectively. A quarter of the rats in each group were sacrificed on the 1st postoperative day. The rest were sacrificed on the 3rd, 5th and 7th postoperative days. The remnant regenerating liver mass was removed and weighed, and Ki-67 monoclonal antibody levels were measured. Results: There was no statistical difference between the four groups on the first day in evaluating the weight of the liver mass (p = 0.09) and Ki-67 (p = 0.268) levels. Only the omeprazole group showed a difference; the Ki-67 level was lower in the omeprazole group on the 3rd (p = 0.003, p = 0.0001, p = 0.003), 5th (p = 0.017, p = 0.001, p = 0.0001) and 7th (p = 0.0001) days compared to the other groups. Also the weight of the remnant liver mass was lower in the omeprazole group on the 3rd, 5th and 7th (p = 0.0001) days. Conclusion: We figured out that lansoprazole and pantoprazole have no effects on liver regeneration, whereas omeprazole showed a negative effect on hepatic regeneration.

show abstract

Inhibitors of Gastric Acid Secretion

Roberts¹,

McDonald²

2003

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

The discovery of potent and selective inhibitors of gastric acid secretion now negates the need for surgical intervention in the treatment of many hypersecretory disorders. The side effects associated with cholinergic antagonists has led to their being superseded by the use of selective histamine H 2 ‐receptor antagonists (cimetidine, ranitidine, famotidine) and the more potent irreversible proton‐pump inhibitors (omeprazole, rabeprazole, lansoprazole, pantoprazole, esomeprazole). Current therapeutic regimes for the treatment of ulcer disease recommend concurrent proton‐pump administration while eradicating Helicobacter pylori , a bacterial infection that is strongly associated with ulcer formation. Because achlorhydria increases the likelihood of gastrointestinal infection, current research within this area is now targeting the design of reversible proton‐pump inhibitors and CCK 2 /gastrin‐receptor antagonists. These newer therapeutic approaches, however, are unlikely to produce the rapid and potent inhibition of acid secretion realized by the irreverisble PPIs, which in addition have few side effects and a proven track record of success. Key drug developments in the treatment of acid hypersecretion, from the anticholinergic agents to the highly potent and effective proton‐pump inhibitors currently in use, are covered in this chapter.

show abstract

Review article: the pharmacology of rabeprazole

Cited by 74 publications

References 36 publications

Potent Gastric Acid Inhibition in Helicobacter pylori Eradication

Potent Gastric Acid Inhibition in Helicobacter pylori Eradication

Effect of Proton Pump Inhibitors on Hepatic Regeneration

Inhibitors of Gastric Acid Secretion

Contact Info

Product

Resources

About